Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Notes Payables (2018 - 2025)

Historic Notes Payables for ImmunoTech (AIM) over the last 5 years, with Q3 2025 value amounting to $1.9 million.

  • ImmunoTech's Notes Payables fell 2749.71% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 2749.71%. This contributed to the annual value of $2.3 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, ImmunoTech's Notes Payables stood at $1.9 million, which was down 2749.71% from $2.3 million recorded in Q2 2025.
  • Over the past 5 years, ImmunoTech's Notes Payables peaked at $2.6 million during Q3 2024, and registered a low of $1.6 million during Q1 2024.